Epstein-Barr virus in the multiple sclerosis brain: A controversial issue-report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria

Brain

Volumn 134, Issue 9, 2011, Pages 2772-2786

  Lassmann, Hans ^a   Niedobitek, Gerald ^b   Aloisi, Francesca ^c   Middeldorp, Jaap M ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

EBV biology; EBV detection in tissue; Epstein Barr virus; multiple sclerosis

Indexed keywords

VIRUS RNA;

ARTICLE; AUSTRIA; BRAIN INFECTION; CELLULAR DISTRIBUTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNE RESPONSE; LYMPHOMA; MEMORY CELL; MORPHOLOGY; MULTIPLE SCLEROSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION;

EID: 80052959919     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr197     Document Type: Article

References (122)

1. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nature Rev 2006; 6: 205-17. (Pubitemid 43290990)
2. Aloisi F, Serafini B, Magliozzi R, Howell OW, Reynolds R. Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain 2010; 133: e157.
3. Ascherio A, Munger KL. Epstein Barr virus infection and multiple sclerosis. J Neuroimmune Pharmacol 2010; 5: 271-7.
4. Bonnet M, Guinebretiere JM, Kremmer E, Grunewald V, Benhamou E, Contesso G, et al. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 1999; 91: 1376-81. (Pubitemid 29399995)
5. Brink AA, Dukers DF, van den Brule AJ, Oudejans JJ, Middeldorp JM, et al. Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. J Clin Pathol 1997; 50: 911-8. (Pubitemid 27524011)
6. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998; 9: 405-11. (Pubitemid 28462761)
7. Casola S, Otipoby KL, Alimzhanov M, Humme S, Uytterspot N, Kutok JL, et al. B cell receptor signal strength determines B cell fate. Nat Immunol 2004; 5: 317-27. (Pubitemid 38332129)
8. Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 2009; 29: 3442-52.
9. Chaganti S, Heath EM, Bergler W, Kuo M, Buettner M, Niedobitek G, et al. Epstein-Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence. Blood 2009; 113: 6372-81.
10. Chen T, Hudnall SD. Anatomical mapping of human herpesvirus reservoirs of infection. Mod Pathol 2006; 19: 726-37.
11. de Sanjosé S, Bosch R, Schouten T, Verkuijlen S, Nieters A, Foretova L, et al. Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls. Int J Cancer 2007; 121: 1806-12. (Pubitemid 47417301)
12. Dukers DF, Meij P, Vervoort MB, Vos W, Scheper RJ, Meijer CJ, et al. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol 2000; 165: 663-70. (Pubitemid 30484731)
13. Esiri MM. Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet 1977; 2: 478.
14. Evans AS, Niederman JC. Epstein-Barr virus. In: Evans AS, Kaslow RA, editors. Viral infections of humans: epidemiology and control, 3rd edn. Plenum Press; 1989. p. 265-92.
15. Flanagan J, Middeldorp J, Sculley T. Localization of the Epstein-Barr virus protein LMP 1 to exosomes. J Gen Virol 2003; 84: 1871-9. (Pubitemid 36805923)
16. Frangou P, Buettner M, Niedobitek G. Epstein-Barr virus (EBV) infection in epithelial cells in vivo: rare detection of EBV replication in tongue mucosa but not in salivary glands. J Infect Dis 2005; 191: 238-42. (Pubitemid 40096382)
17. Frischer JM, Bramow S, Dal Bianco A, Lucchinetti C, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neuro-degeneration in multiple sclerosis. Brain 2009; 132: 1175-89.
18. Gilligan K, Rajadurai P, Resnick L, Raab-Traub N. Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc Natl Acad Sci USA 1990; 87: 8790-4. (Pubitemid 120007594)
19. Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a con-stitutively active receptor molecule. EMBO J 1997; 16: 6131-40. (Pubitemid 27458333)
20. Glaser R, Padgett DA, Litsky ML, Baiocchi RA, Yang EV, Chen M, et al. Stress-associated changes in the steady-state expression of latent Epstein-Barr virus: implications for chronic fatigue syndrome and cancer. Brain Behav Immun 2005; 19: 91-103. (Pubitemid 40138643)
21. Grässer FA, Murray PG, Kremmer E, Klein K, Remberger K, Feiden W, et al. Monoclonal antibodies directed against Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 1994; 84: 3792-8. (Pubitemid 24362478)
22. Grinstein S, Preciado MV, Gattuso P, Chabay PA, Warren PA, De Matteo E, et al. Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res 2002; 62: 4876-8. (Pubitemid 34984406)
23. Gruhne B, Kamranvar SA, Masucci MG, Sompallae R. EBV and genomic instability-a new look at the role of virus in the pathogenesis of Burkitt's lymphoma. Semin Cancer Biol 2009; 19: 394-400.
24. Gulley ML, Glaser SL, Craig FE, Borowitz M, Mann RB, Shema SJ, et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immu-nohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol 2002; 117: 259-67. (Pubitemid 34823667)
25. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 2008; 10: 279-92. (Pubitemid 352022708)
26. Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 2009; 5: e1000496.
27. Hamilton-Dutoit SJ, Pallesen G. Detection of Epstein-Barr virus small RNAs in routine paraffin sections using non-isotype RNA/RNA in situ hybridization. Histopathology 1994; 25: 101-11. (Pubitemid 24261457)
28. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. An up-dated metaanalysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One 2010; 5: e12496.
29. He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003; 171: 5215-24. (Pubitemid 37432806)
30. Hennard C, Pfuhl T, Buettner M, Becker KF, Knöfel T, Middeldorp J, et al. The antibody 2B4 directed against the Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV association of human cancers. J Pathol 2006; 209: 430-5. (Pubitemid 44194557)
31. Herbst H, Dallenbach F, Niedobitek G, Anagnostopoulos I, Hummel M, Finn T, et al. Expression of latent membrane proteins (LMP) od Epstein-Barr virus in malignant lymphomas. Verh Dtsch Ges Pathol 1991; 75: 175-8.
32. Herrmann K, Frangou P, Middeldorp J, Niedobitek G. Epstein-Barr virus replication in tongue epithelial cells. J Gen Virol 2002; 83: 2995-8. (Pubitemid 36054344)
33. Heussinger N, Büttner M, Ott G, Brachtel E, Pilch BZ, Kremmer E, et al. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol 2004; 203: 696-9. (Pubitemid 38714107)
34. Hislop AD, Kuo M, Drake-Lee AB, Akbar AN, Bergler W, Hammerschmitt N, et al. Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. J Clin Invest 2005; 115: 2546-55. (Pubitemid 41266217)
35. Hislop AD, Palendira U, Leese AM, Arkwright PD, Rohrlich PS, Tangye SG, et al. Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 2010; 116: 3249-57.
36. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25: 587-617. (Pubitemid 46697918)
37. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA 2004; 101: 239-44. (Pubitemid 38084234)
38. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 2004; 101 (Suppl 2): 14599-606. (Pubitemid 39346730)
39. Höllsberg P, Hansen HJ, Haahr S. Altered CD8+ T-cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 2003; 132: 137-43. (Pubitemid 36418916)
40. Holmøy T, Kvale EØ, Vartdal F. Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. J Neurovirol 2004; 10: 278-83. (Pubitemid 39429938)
41. Houali K, Wang X, Shimizu Y, Djennaoui D, Nicholls J, Fiorini S, et al. A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. Clin Cancer Res 2007; 13: 4993-5000. (Pubitemid 47502063)
42. Hudnall SD, Ge Y, Wei L, Yang NP, Wang HQ, Chen T. Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils. Mod Pathol 2005; 18: 519-27. (Pubitemid 40478115)
43. Hutt-Fletcher LM. Epstein-Barr virus entry. J Virol 2007; 81: 7825-32. (Pubitemid 47101468)
44. Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T, et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009; 206: 2091-9.
45. Jafari N, van Nierop GP, Verjans GM, Osterhaus AD, Middeldorp JM, Hintzen RQ. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis. J Clin Virol 2010; 49: 26-31.
46. Jaquiery E, Jilek S, Schluep M, Meylan P, Lysandropoulos A, Pantaleo G, et al. Intrathecal immune responses to EBV in early MS. Eur J Immunol 2010; 40: 878-87.
47. Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A, et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008; 131: 1712-21. (Pubitemid 351957461)
48. Kang MS, Hung SC, Kieff E. Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc Natl Acad Sci USA 2001; 98: 15223-8.
49. Khan G. Epstein-Barr virus and the germinal center B cells. Exp Hematol 2006; 34: 695-6. (Pubitemid 43737089)
50. Khan G, Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. Is EBV persistence in vivo a model for B cell homeostasis? Immunity 1996; 5: 173-9. (Pubitemid 26301093)
51. Khan G, Coates PJ, Gupta RK, Kangro HO, Slavin G. Presence of Epstein-Barr virus in Hodgkin's disease is not exclusive to Reed-Sternberg cells. Am J Pathol 1992; 140: 757-62.
52. Khan G, Coates PJ, Kangro HO, Slavin G. Epstein Barr virus (EBV) encoded small RNAs: targets for detection by in situ hybridisation with oligonucleotide probes. J Clin Pathol 1992; 45: 616-20.
53. Kis LL, Salamon D, Persson EK, Nagy N, Scheeren FA, Spits H, et al. IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C-and activation of LMP-1-promoter. Proc Natl Acad Sci USA 2010; 107: 872-7.
54. Kis LL, Takahara M, Nagy N, Klein G, Klein E. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. Immunol Lett 2006; 104: 83-8. (Pubitemid 43330713)
55. Kurth J, Spieker T, Wustrow J, Strickler GJ, Hansmann LM, Rajewsky K, et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 2000; 13: 485-95.
56. Laichalk LL, Hochberg D, Babcock GJ, Freeman RB, Thorley-Lawson DA. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity 2002; 16: 745-54. (Pubitemid 34626694)
57. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 2005; 79: 1296-307. (Pubitemid 40053911)
58. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3: 940-3. (Pubitemid 35154007)
59. Lassmann H, Brück W, Lucchinetti C. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210-8. (Pubitemid 46466140)
60. Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A. Primary infection with Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010; 67: 824-30.
61. Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 2011; 134: 534-41.
62. Lu J, Murakami M, Verma SC, Cai Q, Haldar S, Kaul R, et al. Epstein-Barr virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through upregulation of survivin. Virology 2011; 410: 64-75.
63. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17. (Pubitemid 30390191)
64. Maghzi AH, Marta M, Bosca I, Etemadifar M, Dobson R, Maggiore C, et al. Viral pathophysiology of multiple sclerosis: a role for Epstein-Barr virus infection? Pathophysiology 2010; 18: 13-20.
65. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68: 477-93.
66. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130: 1089-104. (Pubitemid 47355604)
67. Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated prolifera-tive disorders. Crit Rev Oncol Hematol 2003; 45: 1-36. (Pubitemid 35449786)
68. Middeldorp JM, Pegtel DM. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. Semin Cancer Biol 2008; 18: 388-96.
69. Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L. Lytic cycle switches of oncogenic human gammaherpesviruses. Adv Cancer Res 2007; 97: 81-109. (Pubitemid 46528986)
70. Morré SA, van Beek J, De Groot CJ, Killestein J, Meijer CJ, Polman CH, et al. Is Epstein-Barr virus present in the CNS of patients with MS? Neurology 2001; 56: 692. (Pubitemid 32210014)
71. Murray PG, Lissauer D, Junying J, Davies G, Moore S, Bell A, et al. Reactivity with a monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. Cancer Res 2003; 63: 2338-43. (Pubitemid 36538647)
72. Murray PG, Niedobitek G, Kremmer E, Grässer F, Reynolds GM, Cruchley A, et al. In situ detection of the Epstein-Barr virus-encoded nuclear antigen 1 in oral hairy leukoplakia and virus-associated carcinomas. J Pathol 1996; 178: 44-7. (Pubitemid 26052080)
73. Muzio L, Soria JM, Pannese M, Piccolo S, Mallamaci A. A mutually stimulating loop involving emx2 and canonical wnt signalling specifically promotes expansion of occipital cortex and hippocampus. Cereb Cortex 2005; 15: 2021-8. (Pubitemid 41628340)
74. Nicholls J, Kremmer E, Meseda CA, Mackett M, Hahn P, Gulley ML, et al. Comparative analysis of the expression of the Epstein-Barr virus (EBV) anti-apoptotic gene BHRF1 in nasopharyngeal carcinoma and EBV-related lymphoid diseases. J Med Virol 2001; 65: 105-13.
75. Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. Epstein-Barr virus (EBV) infection in infectious mononucle-osis: virus latency, replication and phenotype of EBV-infected cells. J Pathol 1997; 182: 151-9. (Pubitemid 27287835)
76. Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, et al. Heterogeneous expression of Epstein-Barr virus latent protein in endemic Burkitt's lymphoma. Blood 1995; 86: 659-65.
77. Niedobitek G, Agathanggelou A, Steven N, Young LS. Epstein-Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial cells. J Clin Pathol: Mol Pathol 2000; 53: 37-42. (Pubitemid 30075073)
78. Niedobitek G, Herbst H. In situ detection of Epstein-Barr virus and phenotype determination of EBV-infected cells. Methods Mol Biol 2006; 326: 115-37.
79. Niedobitek G, Herbst H, Young LS, Brooks L, Masucci MG, Crocker J, et al. Patterns of Epstein-Barr virus infection in non-neoplastic lymph-oid tissue. Blood 1992; 79: 2520-6.
80. Niedobitek G, Kremmer E, Herbst H, Whitehead L, Dawson CW, Niedobitek E, et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 1997; 90: 1664-72. (Pubitemid 27355441)
81. Niedobitek G, Young LS, Lau R, Brooks L, Greenspan D, Greenspan JS, et al. Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. J Gen Virol 1991; 72: 3035-46.
82. Niller HH, Wolf H, Minarovits J. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin Cancer Biol 2009; 19: 158-64.
83. Obermeier B, Mentele R, Malotka J, Kellermann J, Kümpfel T, Wekerle H, et al. Matching of oligoclonal immunoglobulin transcrip-tomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 2008; 14: 686-93.
84. Owens GP, Bennett JL, Lassmann H, O'Connor KC, Ritchie AM, Shearer A, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 2009; 65: 639-49.
85. Panagopoulos D, Victoratos P, Alexiou M, Kollias G, Mosialos G. Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo. J Virol 2004; 78: 13253-61. (Pubitemid 39507830)
86. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ. Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 2009; 5: e1000492.
87. Peferoen LA, Lamers F, Lodder LN, Gerritsen WH, Huitinga I, Melief J, et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 2010; 133: 1-4.
88. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 2010; 107: 6328-33.
89. Pegtel DM, Subramanian A, Sheen TS, Tsai CH, Golub TR, Thorley-Lawson DA. Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma. J Virol 2005; 79: 15430-42. (Pubitemid 43032325)
90. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune disease. Trends Immunol 2003; 24: 584-8. (Pubitemid 37338526)
91. Pender MP. The essential role of Epstein-Barr Virus in the pathogenesis of multiple sclerosis. Neuroscientist 2011; 17: 351-367.
92. Portis T, Ikeda M, Longnecker R. Epstein-Barr virus LMP2A: regulatory cellular ubiquitination process for maintenance of viral latency? Trends Immunol 2004; 25: 422-6. (Pubitemid 38951083)
93. Preciado MV, Chabay PA, De Matteo EN, Gonzales P, Grinstein S, Actis A, et al. Epstein-Barr virus in breast carcinoma in Argentinia. Arch Pathol Lab Med 2005; 129: 377-81. (Pubitemid 40343994)
94. Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978; 38: 409-21. (Pubitemid 8338235)
95. Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, et al. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin Cancer Biol 2008; 18: 397-408.
96. Roughan JE, Torgbor C, Thorley-Lawson DA. Germinal center B cells latently infected with Epstein-Barr virus proliferate extensively but do not increase in number. J Virol 2010; 84: 1158-68.
97. Salvetti M, Giovannoni G, Aloisi F. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 2009; 22: 201-6.
98. Sargsyan SA, Shearer AJ, Ritchie AM, Burgoon MP, Anderson S, Hemmer B, et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010; 74: 1127-35.
99. Saridakis V, Sheng Y, Sarkari F, Holowaty MN, Shire K, Nguyen T, et al. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1: implications for EBV-mediated immortalization. Mol Cell 2005; 18: 25-36. (Pubitemid 40444645)
100. Sears J, Ujihara M, Wong S, Ott C, Middeldorp J, Aiyar A. The amino terminus of Epstein-Barr virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes. J Virol 2004; 78: 11487-505. (Pubitemid 39390736)
101. Serafini B, Severa M, Columba-Cabezas S, Rosicarelli B, Veroni C, Chiappetta G, et al. Epstein-Barr virus latent infection and BAFF expression in B-cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropath Exp Neurol 2010; 69: 677-93.
102. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204: 2899-912. (Pubitemid 350179559)
103. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14: 164-74. (Pubitemid 38656388)
104. Shaw KM, Stewart SE, Wei W, Woodman CB, O'Neil JD, Dawson CW, et al. The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation. Oncogene 2009; 28: 3903-14.
105. Simon KC, van der Mei IA, Munger KL, Ponsonby A, Dickinson J, Dwyer T, et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 2010; 74: 1365-71.
106. Sivachandran N, Sarkari F, Frappier L. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathog 2008; 4: e1000170.
107. Stevens SJ, Smits PH, Verkuijlen SA, Rockx DA, van Gorp EC, Mulder JW, et al. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription. AIDS 2007; 21: 2141-9. (Pubitemid 350287211)
108. Stevens SJ, Verschuuren EA, Verkuujlen SA, Van Den Brule AJ, Meijer CJ, Middeldorp JM. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma 2002; 43: 831-40. (Pubitemid 34428672)
109. Swaminathan S. Noncoding RNAs produced by oncogenic human her-pesviruses. J Cell Physiol 2008; 216: 321-6. (Pubitemid 351898457)
110. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001; 1: 75-82. (Pubitemid 33741978)
111. Thorley-Lawson DA, Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 2008; 6: 913-24.
112. Tobollik S, Meyer L, Buettner M, Klemmer S, Kempkes B, Kremmer E, et al. Epstein-Barr virus nuclear antigen 2 inhibits AID expression during EBV-driven B-cell growth. Blood 2006; 108: 3859-64. (Pubitemid 44864569)
113. Torkildsen O, Stansberg C, Angelskar SM, Kooi EJ, Geurts JJ, van der Valk P, et al. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathol 2010; 20: 720-9.
114. Tsai CL, Li HP, Lu YJ, Hsueh C, Liang Y, Chen CL, et al. Activation of DNA methyltransferase 1 by EBV LMP1 involves c-jun NH(2)-terminal kinase signaling. Cancer Res 2006; 66: 11668-76. (Pubitemid 46094178)
115. Ufret-Vincenty RL, Quigley L, Tresser N, Pak SH, Gado A, Hausmann S, et al. In vivo survival of viral antigen-specific T cells that induce experimental autoimmune encephalomyelitis. J Exp Med 1998; 188: 1725-38. (Pubitemid 28516117)
116. Wang H, Nicholas MW, Conway KL, Sen P, Diz R, Tisch RM, et al. EBV latent membrane protein 2A induces autoreactive B cell activation and TLR hypersensitivity. J Immunol 2006; 177: 2793-802. (Pubitemid 44277794)
117. Webster-Cyriaque J, Middeldorp J, Raab-Traub N. Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. J Virol 2000; 74: 7610-8. (Pubitemid 30613107)
118. Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenlöhner S, Mallozzi SS, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009; 132: 3318-28.
119. Yates JL, Guan N. Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J Virol 1991; 65: 483-8.
120. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-68. (Pubitemid 39331148)
121. Zhang JX, Chen HL, Zong YS, Chan KH, Nicholls J, Middeldorp JM, et al. Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J Med Virol 1998; 55: 227-33. (Pubitemid 28270768)
122. Zeng Y, Middeldorp J, Madjar JJ, Ooka T. A major DNA binding protein encoded by BALF2 open reading frame of Epstein-Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D, and DNA polymerase. Virology 1997; 239: 285-95. (Pubitemid 28105635)